Secukinumab’s growing number of indications and its body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars, including 4 recently launched adalimumab biosimilars in the European Union.
This week, Novartis announced that the European Commission (EC) approved a label update for secukinumab, sold as Cosentyx. Secukinumab is a targeted biologic therapy for the treatment of psoriatic arthritis (PsA) that inhibits IL-17A, a cytokine involved in inflammation of entheses.
According to Novartis, the label update is significant, as PsA can lead to mobility loss and irreversible joint damage if not treated properly. PsA is a chronic, progressive disease that leads to pain and fatigue as well as activity impairment and significant mobility loss due to structural damage.
“Cosentyx has shown that it can slow the progression of joint damage inflicted by psoriatic arthritis, which can lead to significant mobility loss for patients,” said Paul Emery, professor of rheumatology at the University of Leeds in the United Kingdom.
The update includes dosing flexibility of up to 300 mg based on clinical response that will provide clinicians with dosing flexibility, as well as 24-week structural disease progression data with subcutaneous regimens demonstrating that secukinumab inhibits the progression of joint damage in PsA.
The trial, FUTURE 5, is the largest phase 3 study for a biologic conducted in PsA to date, with an enrollment of 996 patients. The study found that nearly 90% of patients treated with 300 mg of secukinumab had no radiographic disease progression at 24 weeks.
“Cosentyx is the only IL-17A inhibitor to demonstrate a 5-year safety and efficacy in phase 3 studies of PsA and [ankylosing spondylitis]. We are reimagining the well-being of patients living with all facets of psoriatic arthritis,” said Eric Hughes, Global Development Unit Head, Immunology, Hepatology, and Dermatology.
The updated label applies to all European Union and European Economic Area countries and takes effect immediately.
Secukinumab’s growing number of indications and its body of positive data may help it to compete for a substantial share of the inflammatory disease market against an increasing number of US- and EU-approved biosimilars, including 4 recently launched adalimumab biosimilars in the European Union.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.